We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Detect Stroke Type Before Hospital Arrival

By LabMedica International staff writers
Posted on 31 Jan 2025

The longer the time between a stroke's onset and diagnosis, the greater the damage to brain tissue, which worsens the patient's prognosis. More...

It's crucial to distinguish between a hemorrhagic (bleeding) stroke and an ischemic (clot-caused) stroke before initiating treatment, as this decision significantly affects the approach. Generally, this distinction is made using imaging techniques, which can be delayed as the patient is stabilized, transported to the emergency room, and then sent for a brain scan — all while brain cells continue to die. A new blood test may now allow for rapid differentiation between brain bleeds and clot-caused strokes, even before patients with stroke symptoms arrive at the emergency room, as indicated by a preliminary study presented at the American Stroke Association's International Stroke Conference in 2025.

Researchers at RKH Hospital Klinikum Ludwigsburg (Ludwigsburg, Germany) explored whether blood levels of glial fibrillary acidic protein (GFAP) could help quickly diagnose stroke types. GFAP is a protein specific to the brain, which is released into the bloodstream when brain cells are damaged or destroyed. This protein is already used to assess traumatic brain injuries. In a parallel study published in 2024, the research team demonstrated that GFAP levels could quickly distinguish between patients with a bleeding stroke and those who were unresponsive. The focus of this new study was to determine if GFAP levels could differentiate between hemorrhagic stroke (due to bleeding), ischemic stroke (caused by a blood clot), and conditions that mimic a stroke. Blood samples were collected by the emergency medical services ambulance team before the patients arrived at the hospital.

The analysis revealed that GFAP levels were nearly 7 times higher in patients with a bleeding stroke compared to those with a clot-caused stroke (208 picograms per milliliter, or pg/mL, vs. 30 pg/mL) and more than 4 times higher in bleeding stroke patients compared to those with stroke mimics (208 pg/mL vs. 48 pg/mL). The researchers were able to rule out a bleeding stroke in patients with moderate to severe neurological deficits if the GFAP levels were below 30 pg/mL. Additionally, when using age-based cut-off points, they achieved 90%-95% accuracy in predicting which patients had a bleeding stroke. These age-based groups were evenly distributed: under age 72, between 72 and 83, and above 83. Interestingly, the cutoff for those under age 72 was quite low. The researchers also found that GFAP levels were higher in bleeding stroke patients who were on blood thinners compared to those not using these medications. If these findings are confirmed through larger studies, early GFAP measurements could revolutionize the treatment of individuals with stroke symptoms.

“This study reveals that levels of GFAP, a marker for brain injury, are higher in patients with brain hemorrhages compared to those who have strokes caused by blood clots,” said American Heart Association expert volunteer Louise D. McCullough, M.D., P.H.D., FAHA. “This finding suggests that GFAP could serve as a useful prehospital test for assessing brain injuries. However, the study had a relatively small sample size, and for the test to be effective, both the patient's blood and the GFAP test must be available as a “point of care” test in the field. Currently, most ambulances and emergency medical services do not have access to this blood test.”

Related Links:
RKH Hospital Klinikum Ludwigsburg


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: This image shows a second-generation version of the device that can also measure cell morphology (Photo courtesy of MIT)

Rapid Cell Density Measurement Technique to Help Predict Immunotherapy Response

The density of a cell provides valuable insights into its condition. As cells go through processes such as proliferation, differentiation, or cell death, they may gain or lose water and other molecules,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.